Inhaled insulin approved in US


The US Food and Drug administration (FDA) has approved an insulin inhaler for managing diabetes mellitus. Mannkind’s Afrezza is aimed at reducing the need for patients to inject themselves with insulin so frequently. In Europe, the Committee for Medicinal Products for Human Use has recommended that a ‘biosimilar’ long-acting insulin be approved, although this product is the subject of a patent infringement lawsuit in the US.

Inhalable insulin has been a target for pharma companies for several years. Pfizer’s Exubera was approved in 2006, but was withdrawn in January 2008 because of its high cost and concerns over links to lung cancer. Mannkind has taken three attempts to get Afrezza approved by the FDA, after being sent back to complete further clinical trials. While the FDA has approved Afrezza, the decision comes with significant limitations. It still requires patients to inject a long-acting insulin as well as the inhaler, and cannot be used by patients with chronic lung diseases like asthma.

Eli Lilly and Boehringer-Ingelhiem’s long acting Abasria insulin injection has the same amino acid sequence as Sanofi’s Lantus (insulin glargine), which means that it is classed as a biosimilar for regulatory purposes in Europe. Abasria is the first insulin product to pass through Europe’s biosimilars regulatory pathway. Because of differing definitions, it is not classed as a biosimilar in the US, which led Sanofi to file a patent infringement lawsuit against Lilly in January. 


Related Content

Sanofi snaps up inhaled insulin licence

12 August 2014 Business

news image

Deal gives Mannkind access to global manufacturing and distribution for recently-approved Afrezza

Business roundup

28 March 2012 Business

news image

Industry news, April 2012

Most Read

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Copper catalysis overcomes double bond trouble

3 July 2015 Research

news image

Stubbornly stable unactivated internal alkenes become chiral tertiary amine precursors

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...